Moderna, Inc. (NASDAQ:MRNA) Receives $59.00 Average PT from Analysts

Moderna, Inc. (NASDAQ:MRNA) has been given an average recommendation of “Hold” by the twenty-four research firms that are covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $59.00.

Several research analysts have recently commented on MRNA shares. UBS Group lowered their price target on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Morgan Stanley dropped their price target on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. Finally, Bank of America cut their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 11th.

Moderna Price Performance

NASDAQ MRNA opened at $32.12 on Friday. The stock has a market capitalization of $12.42 billion, a P/E ratio of -3.46 and a beta of 1.86. The firm’s 50-day moving average is $34.78 and its two-hundred day moving average is $44.93. Moderna has a 12 month low of $29.25 and a 12 month high of $170.47.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB boosted its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares during the last quarter. Compass Planning Associates Inc purchased a new stake in Moderna during the fourth quarter worth $37,000. Larson Financial Group LLC grew its holdings in Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares during the last quarter. Finally, Crowley Wealth Management Inc. purchased a new position in shares of Moderna in the fourth quarter valued at $41,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.